Πέμπτη 3 Νοεμβρίου 2016

Gender as a risk factor for adverse intraoperative and postoperative outcomes of elective pancreatectomy

Background and Objectives

Patient selection remains paramount when developing and adopting quality-based assessment and reimbursement models, and enhanced recovery protocols. Gender is a patient characteristic known before surgery which can inform risk stratification. Our aim was to evaluate the effect of gender on intraoperative blood transfusions, operative time, length of hospital stay, estimated blood loss (EBL) as well as postoperative surgical site infections (SSIs), and mortality.

Methods

Patients undergoing elective pancreatectomy from 2005 to 2013 were identified in the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) and Northwestern institutional databases. Multivariable analyses were conducted to identify the association between gender and these outcomes.

Results

Analyses demonstrated that male gender was independently associated with blood transfusion (OR 1.23), operative time >6 hr (OR 1.76), length of stay greater than 11 days (OR 1.17), and all-type SSIs (OR 1.17), especially superficial SSIs (OR 1.15) and organ space SSIs (OR 1.18). Analysis of the institutional cohort found that male gender was independently associated with increased odds of EBL > 1 L for Whipple procedures (OR 2.85).

Conclusions

Male gender is a significant predictor of increased operative time, length of stay, transfusions, EBL > 1L, as well as postoperative organ space surgical site infections in these patients. J. Surg. Oncol. © 2016 Wiley Periodicals, Inc.



from Cancer via ola Kala on Inoreader http://ift.tt/2ekcZHY
via IFTTT

Quality End-of-Life Cancer Care: An overdue imperative

S10408428.gif

Publication date: Available online 3 November 2016
Source:Critical Reviews in Oncology/Hematology
Author(s): Guy B. Faguet
This review assesses the current status of end-of-life care based on large-scale, multiyear nationwide surveys of treatment modality, setting, and cost of care during terminal patients' last months of life. It shows that end-of-life care goals often remain suboptimal. Contributing factors include prioritized life preservation, uneven commitment to palliative care, few palliative care specialists, and perverse financial incentives that encourage costly interventions. Although not determinant per se, these factors coupled to doubts about what constitutes end-of-life can lead to overextended disease treatment and a late implementation of palliative care. In order to bridge the existing gap between care received and care expected and achieve quality end-of-life and promote death with dignity, we propose both to view the person rather than the disease as the unit of care and a pragmatic definition of end-of-life. Such a strategy should facilitate selecting an optimal time to transition from disease-targeted treatment to palliative care.



from Cancer via ola Kala on Inoreader http://ift.tt/2fi8Hp4
via IFTTT

Cancer treatment induced metabolic syndrome: improving outcome with lifestyle

S10408428.gif

Publication date: Available online 3 November 2016
Source:Critical Reviews in Oncology/Hematology
Author(s): N.L. Westerink, J. Nuver, Lefrandt, A.H. Vrieling, J.A. Gietema, A.M.E. Walenkamp
Increasing numbers of long-term cancer survivors face important treatment related adverse effects. Cancer treatment induced metabolic syndrome (CTIMetS) is an especially prevalent and harmful condition. The aetiology of CTIMetS likely differs from metabolic syndrome in the general population, but effective treatment and prevention methods are probably similar. In this review, we summarize the potential mechanisms leading to the development of CTIMetS after various types of cancer treatment. Furthermore, we propose a safe and accessible method to treat or prevent CTIMetS through lifestyle change. In particular, we suggest that a lifestyle intervention and optimization of energy balance can prevent or mitigate the development of CTIMetS, which may contribute to optimal survivorship care.



from Cancer via ola Kala on Inoreader http://ift.tt/2f7bPRK
via IFTTT

Video-assisted thoracic surgery lobectomy in patients with reduced pulmonary function: a single-center series

Future Oncology Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2f0sjO7
via IFTTT

Deregulated miRNAs in human cervical cancer: functional importance and potential clinical use

Future Oncology Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2fkZ0nO
via IFTTT

Issue Information



from Cancer via ola Kala on Inoreader http://ift.tt/2fJTo9x
via IFTTT

PHGDH and Cancer Progression

Phosphoglycerate dehydrogenase (PHGDH) is the metabolic enzyme responsible for shunting the glycolytic intermediate 3-phosphoglycerate to the serine synthesis pathway. In breast cancer and several other types of cancer, increased PHGDH expression is associated with patient mortality. Early studies focused on the role of PHGDH in promoting cell proliferation in the small percentage of breast cancers with PHGDH gene amplification. However, recent studies have revealed a critical role for PHGDH and downstream enzymes of the serine synthesis pathway and one carbon metabolism in NADPH production and the maintenance of redox homeostasis, which are required for enrichment of breast cancer stem cells in response to hypoxia or chemotherapy. These results provide a mechanism for PHGDH overexpression in breast cancers in which PHGDH is not amplified and have implications for improving the response of triple-negative breast cancers to cytotoxic chemotherapy. Cancer Res; 76(22); 1–5. ©2016 AACR.

from Cancer via ola Kala on Inoreader http://ift.tt/2e7kozd
via IFTTT